<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">healthcare</journal-id><journal-title-group><journal-title xml:lang="ru">Здравоохранение. Healthcare</journal-title><trans-title-group xml:lang="en"><trans-title>Healthcare</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1027-7218</issn><publisher><publisher-name>Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Health Economics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.65249/1027-7218-2026-8-4-11</article-id><article-id custom-type="elpub" pub-id-type="custom">healthcare-355</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИННОВАЦИОННЫЕ МЕДИЦИНСКИЕ ТЕХНОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INNOVATIVE MEDICAL TECHNOLOGIES</subject></subj-group></article-categories><title-group><article-title>Эффективность и безопасность заготовки донорских гранулоцитов методом автоматического афереза</article-title><trans-title-group xml:lang="en"><trans-title>Efficiency and safety of granulocyte collection for transfusion using automated peripheral blood apheresis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1434-9639</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гущина</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Huchchyna</surname><given-names>L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гущина Лариса Михайловна – заместитель директора по трансфузиологии</p><p>Долгиновский тракт, 160, 220053, г. Минск</p><p>Сл. тел. +375 17 347-56-56</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Липницкий</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lipnitski</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Минск</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Еремин</surname><given-names>В. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Eremin</surname><given-names>W.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Долгиновский тракт, 160, 220053, г. Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6805-1782</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Потапнев</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Potapnev</surname><given-names>M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Потапнев Михаил Петрович</p><p>Долгиновский тракт, 160, 220053, г. Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-9225-5951</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каменская</surname><given-names>T. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kamenskaya</surname><given-names>T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Каменская Татьяна Валентиновна</p><p>Долгиновский тракт, 160, 220053, г. Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-8020-2919</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дунаев</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dunayeu</surname><given-names>I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дунаев Игорь Анатольевич</p><p>Долгиновский тракт, 160, 220053, г. Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жданович</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhdanovich</surname><given-names>O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Долгиновский тракт, 160, 220053, г. Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3193-4864</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кирсанова</surname><given-names>Н. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirsanava</surname><given-names>N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кирсанова Наталья Павловна</p><p>Минск</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козловская</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kazlouskaya</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Долгиновский тракт, 160, 220053, г. Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-6883-6259</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Качан</surname><given-names>Г. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Kachan</surname><given-names>H.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Качан Галина Львовна</p><p>Минск</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Республиканский научно-практический центр трансфузиологии и медицинских биотехнологий</institution><country>Belarus</country></aff><aff xml:lang="ru" id="aff-2"><institution>Республиканский научно-практический центр детской онкологии, гематологии и иммунологии</institution><country>Belarus</country></aff><aff xml:lang="ru" id="aff-3"><institution>Белорусский государственный медицинский университет</institution><country>Belarus</country></aff><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>12</day><month>10</month><year>2026</year></pub-date><volume>0</volume><issue>8</issue><fpage>4</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гущина Л.М., Липницкий А.В., Еремин В.Ф., Потапнев М.П., Каменская T.В., Дунаев И.А., Жданович О.А., Кирсанова Н.П., Козловская А.Д., Качан Г.Л., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Гущина Л.М., Липницкий А.В., Еремин В.Ф., Потапнев М.П., Каменская T.В., Дунаев И.А., Жданович О.А., Кирсанова Н.П., Козловская А.Д., Качан Г.Л.</copyright-holder><copyright-holder xml:lang="en">Huchchyna L., Lipnitski A., Eremin W., Potapnev M., Kamenskaya T., Dunayeu I., Zhdanovich O., Kirsanava N., Kazlouskaya A., Kachan H.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://healthcare.ejournal.by/jour/article/view/355">https://healthcare.ejournal.by/jour/article/view/355</self-uri><abstract><p>Цель исследования. Определить эффективность и безопасность заготовки гранулоцитов методом автоматического афереза от здоровых доноров для последующего переливания пациентам онкогематологического профиля с наличием инфекционных осложнений на фоне длительной и глубокой нейтропении.Материал и методы. У 100 добровольных доноров после мобилизации гранулоцитов с использованием гранулоцитарного колониестимулирующего фактора и дексаметазона проведено 110 процедур автоматического афереза на сепараторах крови MSC+ (Haemonetics, США) (n = 56) и Spectra Optia® Apheresis System (Terumo BCT, США) (n = 54). Оценены эффективность и безопасность процедуры мобилизации и афереза лейкоцитов, также проведено сравнение эффективности афереза гранулоцитов в зависимости от вида сепаратора крови.Результаты. Используемый режим мобилизации привел к увеличению содержания лейкоцитов у доноров в 5,2 раза (с 6,4×109/л до 33,0×109/л, р &lt; 0,001), относительного содержания гранулоцитов – в 1,5 раза (с 60,4 до 91,3 %, р &lt; 0,001). Количество ядросодержащих клеток в дозе компонента крови было достоверно выше при использовании сепаратора крови Spectra Optia по сравнению с MCS+ (25,0 [16,4; 34,4]×109 в дозе и 14,9 [10,3; 20,0]×109 в дозе соответственно, р &lt; 0,001). При этом относительное содержание гранулоцитов в конечном компоненте было значимо большим при проведении процедур на аппарате MCS+ по сравнению со Spectra Optia (92,7 % и 84,5 % соответственно, р &lt; 0,001). Побочные эффекты мобилизации гранулоцитов регистрировались в 3 (2,7 %) случаях, при проведении процедуры афереза – у 2 (1,8 %) доноров.Заключение. Режим мобилизации гранулоцитов с использованием гранулоцитарного колониестимулирующего фактора и дексаметазона показал эффективность и безопасность для донора. Аферез гранулоцитов на сепараторах MSC+ и Spectra Optia позволил получить компонент крови с содержанием ядросодержащих клеток не менее 9×109 в дозе и относительном содержании гранулоцитов не менее 60 %, что говорит об эффективности сбора гранулоцитов при указанных способах сепарации. Процедура афереза гранулоцитов показала хорошую переносимость, отсутствие серьезных побочных эффектов, она является безопасной для доноров и может применяться для получения лечебной (достаточной) дозы аллогенных гранулоцитов в комплексном лечении инфекционных осложнений у пациентов с нейтропенией.</p></abstract><trans-abstract xml:lang="en"><p>Objective. To determine the effectiveness and safety of collecting granulocytes by automated apheresis from healthy donors for subsequent transfusion to oncohematological patients with infectious complications associated with prolonged and profound neutropenia.Materials and methods. 110 procedures of automated apheresis were performed on 100 volunteer donors after granulocyte mobilization using granulocyte colony-stimulating factor and dexamethasone. These procedures were conducted on MSC+ blood separators (Haemonetics, USA) (n = 56) and Spectra Optia® Apheresis System (Terumo BCT, USA) (n = 54). The effectiveness and safety of the mobilization and leukocyte apheresis procedures were evaluated, and the effectiveness of granulocyte apheresis was compared based on the type of blood separator used.Results. The mobilization regimen used led to a 5.2-fold increase in leukocyte content in donors (from 6.4×109/l to 33.0×109/l, p &lt; 0.001) and a 1.5-fold increase in the relative granulocyte content (from 60.4 % to 91.3 %, p &lt; 0.001). The number of nucleated cells per blood component dose was significantly higher when using the Spectra Optia blood separator compared to the MCS+ (25.0 [16.4; 34.4]×109/dose and 14.9 [10.3; 20.0]×109/dose, respectively, p &lt; 0.001). However, the relative granulocyte content in the final component was significantly greater when procedures were performed on the MCS+ apparatus compared to Spectra Optia (92.7 % and 84.5 %, respectively, p &lt; 0.001). Adverse events associated with granulocyte mobilization were recorded in three cases (2.7 %), and during the apheresis procedure, in two donors (1.8 %).Conclusion. The granulocyte mobilization regimen using granulocyte colony-stimulating factor and dexamethasone demonstrated effectiveness and safety for the donor. Granulocyte apheresis on MSC+ and Spectra Optia separators yielded a blood component with a nucleated cell content of at least 9×109 per dose and a relative granulocyte content of at least 60 %, indicating the effectiveness of granulocyte collection by these separation methods. The granulocyte apheresis procedure showed good tolerability, an absence of serious adverse effects, is safe for donors, and can be used to obtain a therapeutic (sufficient) dose of allogeneic granulocytes for the complex treatment of infectious complications in patients with neutropenia.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>доноры</kwd><kwd>колониестимулирующий фактор</kwd><kwd>аферезные гранулоциты</kwd><kwd>эффективность</kwd><kwd>безопасность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>donors</kwd><kwd>colony-stimulating factor</kwd><kwd>apheresis granulocytes</kwd><kwd>effectiveness</kwd><kwd>safety</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction / L. J. Estcourt, S. Stanworth, C. Doree [et al.] // Cochrane Database of Systematic Reviews. – 2015. – № 6. – doi: 10.1002/14651858.CD005341.pub3.</mixed-citation><mixed-citation xml:lang="en">Estcourt L.J., Stanworth S., Doree C., et al. Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction. CDSR. 2015; 6. doi: 10.1002/14651858.CD005341.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Granulocyte transfusions in the management of invasive fungal infections / K. A. West, J. Gea-Banacloche, D. Stroncek, S. S. Kadri // The British Journal of Haematology. – 2017. – Vol. 177, № 3. – P. 357–374.</mixed-citation><mixed-citation xml:lang="en">West K.A., Gea-Banacloche J., Stroncek D., Kadri S.S. Granulocyte transfusions in the management of invasive fungal infections. Br J Haematol. 2017; 177(3): 357–374.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Production of viable and functional neutrophils in granulocyte concentrates with the Reveos automated system / S. Fonseca, M.-C. Lampron, I. Pare [et al.] // Vox Sanguinis. – 2025. – Vol. 120, № 11. – P. 1083–1092.</mixed-citation><mixed-citation xml:lang="en">Fonseca S., Lampron M.-C., Pare I., et al. Production of viable and functional neutrophils in granulocyte concentrates with the Reveos automated system. Vox Sang. 2025; 120(11): 1083–1092.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">A retrospective observation of donor variables and patient outcome in granulocyte harvest and its transfusion – a limited experience from a single center / A. A. Pawar, A. G. Naqvi, R. Verghese [et al.] // Asian Journal of Transfusion Science. – 2025. – doi: 10.4103/ajts.ajts_29_25.</mixed-citation><mixed-citation xml:lang="en">Pawar A.A., Naqvi A.G., Verghese R., et al. A retrospective observation of donor variables and patient outcome in granulocyte harvest and its transfusion – a limited experience from a single center. Asian J Transfusion Sci. 2025. doi: 10.4103/ajts.ajts_29_25.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Нейтрофильные гранулоциты как компонент крови для переливания. Технология получения и опыт применения для лечения инфекционных осложнений грибковой этиологии у детей с онкогематологическими заболеваниями / Л. М. Гущина, О. В. Алейникова, М. П. Потапнев [и др.] // Гематология. Трансфузиология. Восточная Европа. – 2019. – Т. 5, № 3. – С. 271–280.</mixed-citation><mixed-citation xml:lang="en">Gushchina L.M., Aleinikova O.V., Potapnev M.P., et al. Neutrophil granulocytes as a blood component for transfusion. Production technology and experience in the treatment of infectious complications of fungal etiology in children with oncohematological diseases. Hematology. Transfusiology. Eastern Europe. 2019; 5(3): 271–280. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Granulocyte transfusions in pediatric hemato-oncology: neutrophil response and CRP kinetics / A. Sever, R. Rabinowicz, Sh. Baezilai-Birenboim [et al.] // Pediatric Blood Cancer. – 2025. – Vol. 72, № 11. – doi: 10.1002/pbc.31979.</mixed-citation><mixed-citation xml:lang="en">Sever A., Rabinowicz R., Baezilai-Birenboim Sh., et al. Granulocyte transfusions in pediatric hemato-oncology: neutrophil response and CRP kinetics. Pediatr Blood Cancer. 2025; 72(11). doi: 10.1002/pbc.31979.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Granulocyte transfusion improves survival in pediatric febrile neutropenia : a 15-year cohort study / W. Phetsai, K. Sanpakit, J. Buaboonnam [et al.] // Clinical and Experimental Pediatrics. – 2026. – Vol. 69, № 3. – P. 236–246.</mixed-citation><mixed-citation xml:lang="en">Phetsai W., Sanpakit K., Buaboonnam J., et al. Granulocyte transfusion improves survival in pediatric febrile neutropenia. Clin Exp Pediatr. 2026; 69(3): 236–246.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions / T. Netelenbos, E. Massey, L. C. de Wreede [et al.] // Transfusion. – 2019. – Vol. 59, № 1. – P. 160–168.</mixed-citation><mixed-citation xml:lang="en">Netelenbos T., Massey E., de Wreede L.C., et al. The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions. Transfusion. 2019; 59(1): 160–168.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Differences in the product characteristics and clinical use of granulocytes for transfusion: The BEST Collaborative study / L. Cain, Ch. Lafrance, S. Morton [et al.] // Transfusion. – 2025. – Vol. 65, № 6. – P. 1111–1123.</mixed-citation><mixed-citation xml:lang="en">Cain L., Lafrance Ch., Morton S., et al. Differences in the product characteristics and clinical use of granulocytes for transfusion. Transfusion. 2025; 65(6): 1111–1123.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience / O. Nikolajeva, A. Mijovic, D. Hess [et al.] // Bone Marrow Transplantation. – 2015. – Vol. 50, № 6. – P. 846–849.</mixed-citation><mixed-citation xml:lang="en">Nikolajeva O., Mijovic A., Hess D., et al. Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation. Bone Marrow Transplant. 2015; 50(6): 846–849.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Granulocyte apheresis in donors: a comparative study of spectra optia and cobe spectra apheresis systems / L. John, A. A. Vaheedu, P. Ramanadhan [et al.] // Transfusion and Apheresis Science. – 2026. – Vol. 65, № 1. – doi: 10.1016/j.transci.2025.104284.</mixed-citation><mixed-citation xml:lang="en">John L., Vaheedu A.A., Ramanadhan P., et al. Granulocyte apheresis in donors: a comparative study of spectra optia and cobe spectra apheresis systems. Transfus Apheresis Sci. 2026; 65(1). doi: 10.1016/j.transci.2025.104284.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pooled granulocyte component – a worthy rival to the apheresis product / A. Szumowski, T. Wasiluk, M. Sredzinska [et al.] // Advances in Medical Sciences. – 2026. – Vol. 71, № 1. – P. 27–39.</mixed-citation><mixed-citation xml:lang="en">Szumowski A., Wasiluk T., Sredzinska M., et al. Pooled granulocyte component – a worthy rival to the apheresis product. Adv Med Sci. 2026; 71(1): 27–39.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Granulocyte concentrates derived from buffy coats versus apheresis granulocytes – differences in product characteristics and costs between two centers in India / V. Shenoy, A. Hazra, A. Vaheedu [et al.] // Indian Journal of Hematology and Blood Transfusion. – 2026. – Vol. 42, № 3. – P. 1018–1024.</mixed-citation><mixed-citation xml:lang="en">Shenoy V., Hazra A., Vaheedu A., et al. Granulocyte Concentrates derived from buffy coats versus apheresis granulocytes – differences in product characteristics and costs between two centers in India. Indian J Hematol Blood Transf. 2026; 42(3): 1018–1024.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection / T. H. Price, M. Boeckh, R. W. Harrison [et al.] // Blood. – 2015. – Vol. 126, № 18. – P. 2153–2161.</mixed-citation><mixed-citation xml:lang="en">Price T.H., Boeckh M., Harrison R.W., et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015; 126(18): 2153–2161.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Neutrophil function is preserved in a pooled granulocyte component prepared from whole blood donations / S. Bashir, S. Stanworth, E. Massey [et al.] // British Journal of Haematology. – 2008. – Vol. 140, № 6. – P. 701–711.</mixed-citation><mixed-citation xml:lang="en">Bashir S., Stanworth S., Massey E., et al. Neutrophil function is preserved in a pooled granulocyte component prepared from whole blood donations. Br J Haematol. 2008; 140(6): 701–711.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Granulocyte transfusion: clinical updates and a practical approach to transfusion / T. Cohen, S. C. Simmons, H. P. Pham, E. M. Staley // Clinics in Laboratory Medicine. – 2021. – Vol. 41, № 4. – P. 647–657.</mixed-citation><mixed-citation xml:lang="en">Cohen T., Simmons S.C., Pham H.P., Staley E.M. Granulocyte transfusion: clinical updates and a practical approach to transfusion. Clin Lab Med. 2021; 41(4): 647–657.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G-CSF (3 µg/kg) plus dexamethasone versus glycosylated G-CSF (12 µg/kg) alone / H.G. Heuft, L. Goudeva, S. Sel, R. Blasczyk // Transfusion. – 2002. – Vol. 42, № 7. – P. 928–934.</mixed-citation><mixed-citation xml:lang="en">Heuft H.G., Goudeva L., Sel S., Blasczyk R. Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G-CSF (3 µg/kg) plus dexamethasone versus glycosylated G-CSF (12 µg/kg) alone. Transfusion. 2002; 42(7): 928–934.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yeghen, T. Granulocyte transfusion : a review / T. Yeghen, S. Devereux // Vox Sanguinis. – 2001. – Vol. 81, № 2. – P. 87–92.</mixed-citation><mixed-citation xml:lang="en">Yeghen T., Devereux S. Granulocyte transfusion. Vox Sang. 2001; 81(2): 87–92.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Репина, Л. А. Иммунофенотипическая характеристика «мобилизированных» нейтрофильных гранулоцитов, используемых для переливания / Л. А. Репина, М. П. Потапнев, Л. М. Гущина // Гематология. Трансфузиология. Восточная Европа. – 2022. – Т. 8, № 1. – С. 29–40.</mixed-citation><mixed-citation xml:lang="en">Repina L.A., Potapnev M.P., Gushchina L.M. Immunophenotypic characteristics of “mobilizedˮ neutrophil granulocytes used for transfusion. Hematology. Transfusiology. Eastern Europe. 2022; 8(1): 29–40. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Spectra Optia granulocyte apheresis collections result in higher collection efficiency of viable, functional neutrophils in a randomized, crossover, multicenter trial / J. A. Cancelas, A. Padmanabhan, T. Le [et al.] // Transfusion. – 2015. – Vol. 55, № 4. – P. 748–755.</mixed-citation><mixed-citation xml:lang="en">Cancelas J.A., Padmanabhan A., Le T., et al. Spectra Optia granulocyte apheresis collections result in higher collection efficiency of viable, functional neutrophils in a randomized, crossover, multicenter trial. Transfusion. 2015; 55(4): 748–755.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Quillen, K. The determinants of granulocyte yield in 1198 granulocyte concentrates collected form unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor : a 13-year experience / K. Quillen, Y. Y. Yau, S. F. Leitman // Transfusion. – 2009. – Vol. 49, № 3. – P. 421–426.</mixed-citation><mixed-citation xml:lang="en">Quillen K., Yau Y.Y., Leitman S.F. The determinants of granulocyte yield in 1198 granulocyte concentrates collected form unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience. Transfusion. 2009; 49(3): 421–426.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Safety and efficacy of hematopoietic stem cell collection form mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors / K. Holig, M. Kramer, F. Kroschinsky [et al.] // Blood. – 2009. – Vol. 114, № 18. – P. 3757–3763.</mixed-citation><mixed-citation xml:lang="en">Holig K., Kramer M., Kroschinsky F., et al. Safety and efficacy of hematopoietic stem cell collection form mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009; 114(18): 3757–3763.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Efficacy and side effects of granulocyte collection in healthy donors / F. Brockmann, M. Kramer, M. Bornhauser [et al.] // Transfusion Medicine and Hemotherapy. – 2013. – Vol. 40, № 4. – P. 258–264.</mixed-citation><mixed-citation xml:lang="en">Brockmann F., Kramer M., Bornhauser M., et al. Efficacy and side effects of granulocyte collection in healthy donors. Transfus Med Hemother. 2013; 40(4): 258–264.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
